海普瑞：注射用H1710获批开展临床试验

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its candidate drug H1710, which is a novel compound targeting acetylheparinase [1] Company Summary - H1710 is an independently developed candidate drug by the company, demonstrating anti-tumor pharmacological activity by inhibiting the activity and expression of acetylheparinase [1] - Preclinical studies have shown that H1710 exhibits significant tumor suppression effects in various tumor animal models [1] - As of the announcement date, there are no similar products on the market with the same molecular mechanism globally [1]